On June 15, 2022, the 2022 Future Medical VB 100 List was unveiled jointly by VB 100, VB Data and VCBeat Research. MGI was named in the List of Future Medical VB 100 - Top 100 Innovative Medical Equipment Companies in China, and honored the Future Medical VB 100 Pengcheng Award - Leading Enterprise of the Year.

Founded in 2015, the Future Medical VB 100 is China's first list of awards targeting  private innovative healthcare companies. The Top 100 Future Medical Companies list includes companies involved in healthcare innovation. In the past seven years, the award list has extended to the global innovative healthcare ecosystem including enterprises, investors, hospitals, and industrial parks. It is the annual life-science and health campaign that lures the highest attention from both the healthcare industry and investor community.

The virtual Future Medical VB 100 conference was designed to tell the stories of life science in China. The award ceremony was held on the evening of June 15. Jiang Hui, COO of MGI, attended the online event and delivered a speech.

Bi Yuanfeng, COO of VB Data, spoke highly of MGI when hosting the interactive session. He said, "MGI is a role model of Chinese innovative technology companies. It's also one of only a few upstream enterprises that continue to develop life-science tools in China."

As a response, Jiang Hui said, "MGI is honored to be featured in Top 100 Chinese Innovative Medical Equipment Companies for the third time. MGI is committed to the vision of leading life science innovation and has been developing and promoting advanced life science tools for future healthcare. Winning this award demonstrates our long-term devotion to innovation and showcases that we are on the right track towards our ambition."

Talking about MGI's future plan, Jiang Hui said, "The key to advanced life science tools lies in the applications. First of all, in the research field, MGI will take a three-pronged approach this year based on genetic sequencers, lab automation and new businesses by scientifically empowering the applications of large-scale population genomics, single-cell omics and spatiotemporal omics. Secondly, in the clinical field, we will target precision genetic testing in such scenarios as reproductive health, oncology, infection, and chronic diseases, and leverage the applications of genetic sequencers and automated equipment to help improve our understanding of humans and diseases and empower disease prevention. Thirdly, in the new application areas such as disease control and agriculture, we hope to use life science tools to identify more possibilities in these fields."

"We firmly believe in the power of innovation and are committed to continuous research and development of new products," Jiang Hui concluded. "In September this year, MGI will launch a new sequencer, so please stay tuned."